Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy
NAR-TRG-Kombinationsscore als Surrogatendpunkt für das krankheitsfreie Überleben bei lokal fortgeschrittenem Rektumkarzinom nach neoadjuvanter Radiochemotherapie
The Oncologist · 04.06.2025 · 30 (6)
DOI: 10.1093/oncolo/oyaf124 ↗Auf einen Blick
Bei 952 Patient:innen mit lokal fortgeschrittenem Rektumkarzinom sagte ein NAR-TRG-Kombinationsscore das 5-Jahres-DFS besser voraus als NAR oder TRG allein. Höhere Scores waren mit schlechterem DFS verbunden.
Fragestellung
Kann ein kombinierter NAR-TRG-Score das krankheitsfreie Überleben (DFS) bei LARC nach neoadjuvanter Radiochemotherapie vorhersagen?
Methode
Analyse von 952 konsekutiven Patient:innen aus 2 Zentren; NAR- und TRG-Gruppen wurden zu einem NAR-TRG-Score kombiniert. DFS wurde mit Kaplan-Meier und Cox-Regression analysiert.
Ergebnisse
5-Jahres-DFS: 91,4 % vs 79,9 % vs 72,3 % für NAR-TRG-Score 1 bis 3 (P < .001). In der multivariaten Analyse war der Score ein unabhängiger Prädiktor des DFS: HR 1,577 (95 %-KI 1,298–1,915; P < .001).
Schlussfolgerung der Autor:innen
Der NAR-TRG-Score stratifiziert Patient:innen mit neoadjuvanter CRT wirksam und kann laut den Autor:innen als Surrogatendpunkt für DFS dienen.
Kernaussagen
- 5-Jahres-DFS nahm mit höherem NAR-TRG-Score ab
- Unabhängiger Prädiktor für DFS: HR 1,577 (95 %-KI 1,298–1,915)
- Besser als NAR oder TRG allein in Haupt- und Validierungskohorte
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 23.06.2025. Verfasst von Weili Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Science and Technology Projects in Guangzhou, Beijing Xisike Clinical Oncology Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Existing prognostic models, such as tumor regression grade (TRG) and neoadjuvant rectal (NAR) score, have been validated as important indicators for assessing the efficacy of neoadjuvant therapy in locally advanced rectal cancer (LARC) and predicting disease-free survival (DFS). However, both models have inherent limitations in prognostic prediction. This study aims to construct a composite NAR-TRG score to predict DFS in LARC patients treated with chemoradiotherapy (CRT) followed by radical surgery. Patients and Methods A total of 952 consecutive LARC patients between December 2010 and July 2018 at Sun Yat-sen University Cancer Center and Fujian Cancer Hospital, were enrolled in this study. After calculating the NAR score, patients were categorized into NAR low, medium, and high groups; TRG was dichotomized into TRG low and high groups; the NAR-TRG combined score was then determined based on both NAR and TRG groupings. Survival outcomes were analyzed using Kaplan–Meier, Cox regression. Nomograms were developed to forecast patient DFS, with the area under the curve values of time-dependent receiver operating characteristic (timeROC) and c-index utilized to assess the accuracy and reliability of the nomograms.
Results
Significant differences in 5-year DFS were observed among the NAR-TRG score from 1 to 3 (91.4% vs 79.9% vs 72.3%, P < .001). NAR-TRG score was identified as an independent predictor of DFS in multivariate analysis (HR = 1.577, 95% CI: 1.298-1.915, P < .001). The comparison of timeROC AUCs revealed that the NAR-TRG score consistently outperformed both the NAR score and TRG group at various time points (Main cohort: NAR-TRG score vs TRG, P = .002; NAR-TRG score vs NAR, P = .002; Validation cohort: NAR-TRG score vs TRG, P = .003; NAR-TRG score vs NAR, P = .002). The nomogram model including the NAR-TRG score demonstrated a superior c-index and area under the timeROC for DFS compared to models excluding the NAR-TRG score both in the main cohort and validation cohort.
Conclusions
The NAR-TRG score effectively stratifies LARC patients receiving neoadjuvant CRT, which can serve as a surrogate endpoint for DFS, contributing to the optimization of decisions related to postoperative therapy and subsequent follow-up strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Canc…
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer, Collaborative Innovation Center for Cancer Medici…
- Department of Intensive Care Medicine (ICU), State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer, Collaborative Innovation Center for…
- Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
ORCID-Profile: Weili Zhang, Jianhong Peng
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Projects in Guangzhou
- Beijing Xisike Clinical Oncology Research Foundation
- Shenzhen Science and Technology Plan Projects
Zitieren
APA
Zhang, W., Sun, H., Yang, R., Xie, X., Liao, L., Wang, W., Wang, R., Wu, X., Lu, Z., Pan, Z., Lin, F., Shao, L., & Peng, J. (2025). Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf124
Vancouver
Zhang W, Sun H, Yang R, Xie X, Liao L, Wang W, et al. Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf124
BibTeX
@article{Zhang2025,
author = {Zhang, Weili and Sun, Hui and Yang, Rong and Xie, Xiaolin and Liao, Leen and Wang, Weifeng and Wang, Ruowei and Wu, Xiaojun and Lu, Zhenhai and Pan, Zhizhong and Lin, Feifei and Shao, Lingdong and Peng, Jianhong},
title = {Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {6},
doi = {10.1093/oncolo/oyaf124}
}
EUVIMED